GlassScriptPhysician profile
Meghan Price
NPI 1225509615
$7,102.02
in general payments reported to CMS, 2019-2025
27 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $875 · 2022: $1,237 · 2023: $1,790 · 2024: $1,665 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,860 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,859.96 |
| Education | $130.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,701.83 | 2021-2025 | Brilinta, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $997.89 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $782.69 | 2021-2025 | |
| Abbott Laboratories | $519.67 | 2023-2025 | Cardiomems, Mitraclip |
| Amgen INC. | $502.31 | 2021-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $360.88 | 2021-2022 | |
| Scpharmaceuticals INC. | $330.04 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $276.05 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $186.04 | 2022-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.65 | 2022-2025 | Lifevest |
| Cvrx, INC. | $148.35 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $137.65 | 2022-2025 | Ozempic |
| Glaxosmithkline, LLC. | $134.50 | 2022-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $124.47 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $113.52 | 2022-2024 | Eliquis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $108.10 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $107.19 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $88.20 | 2021-2023 | Evkeeza |
| Boston Scientific Corporation | $75.80 | 2024 | Watchman Flx |
| Grifols USA, LLC | $65.19 | 2024 | Prolastin-C Liquid |
| Philips North America LLC | $35.49 | 2022-2025 | Coronary Other |
| Viatris Specialty LLC | $30.80 | 2025 | Yupelri |
| Tactile Systems Technology INC | $30.28 | 2025 | Flexitouch Plus, Nimbl |
| Abiomed | $26.80 | 2025 | |
| Kestra Medical Technology Services, INC. | $23.99 | 2025 | Assure Wcd |
| Daiichi Sankyo INC. | $16.73 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $14.91 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.